7 Best Under The Radar Stocks to Buy According to Analysts

2. Sensus Healthcare (NASDAQ:SRTS)  

Upside Potential: 48.91%  

Number of Hedge Fund Investors: 7  

Sensus Healthcare (NASDAQ:SRTS) is a medical device company that provides non-invasive treatments for skin cancer and other skin conditions. The company’s products offer a non-surgical alternative to traditional treatments.

Sensus Healthcare’s (NASDAQ:SRTS) SRT-100+ is a compact and easy-to-use state-of-the-art system that uses Superficial Radiotherapy (SRT) to treat non-melanoma skin cancer and keloids. This provides a non-invasive, outpatient treatment option with a 30”x30” footprint and delivers a precise and calibrated dose of SRT that penetrates only five millimeters below the skin’s surface. This safe and effective treatment destroys malignant skin cancer cells while preserving healthy tissue, making it an ideal solution for basal cell carcinoma treatment and squamous cell carcinoma treatment,

In Q2, Sensus Healthcare’s (NASDAQ:SRTS) revenue increased 104% compared to the same period last year, driven by the increasing demand for the company’s SRT systems. Net income increased to $1.6 million, compared to a net loss of $400,000. Whereas the company’s adjusted EBITDA was $2.1 million, compared to a negative $1.0 million in the same period last year. The company has no debt, which reduces its financial risk and provides it with the flexibility to invest in its business.

The company’s “Fair Deal Agreement” program, which was launched in March, is gaining momentum, with 15 agreements signed to date. This program provides a recurring revenue stream for the company as customers commit to purchasing SRT systems and services over a period of time.

Sensus Healthcare (NASDAQ:SRTS) is also expanding its international presence, with a focus on Asia. The company shipped two units to China and one to Taiwan in Q2 and is working to establish distribution in South Korea and Japan. This expansion will help to drive revenue growth and increase the company’s global market share.

The demand for SRT systems is increasing, driven by the growing need for effective treatments for non-melanoma skin cancer and keloids. Sensus Healthcare’s (NASDAQ:SRTS) is well-positioned to capitalize on this trend, the company also has a competitive advantage in the market as its SRT systems being highly effective and cost-effective.

Industry analysts have a consensus on the stock’s Buy rating, setting an average share price target at $10.67, which represents a 48.91% upside potential from its current levels. As of the second quarter, Sensus Healthcare’s (NASDAQ:SRTS) stock is held by 7 hedge funds, with a total stake valued at $3.94 million.